Interim Report January-September 2010 is published on October 28 2010 at appr. 8am with conference call at 11am (CET)
10/25/2010 5:30 AM EST
Västra Frölunda, Sweden, October 25 2010
Artimplant publishes Interim Report January-September 2010 on October 28 2010 at approximately 8am (CET). The Interim Report is presented by CEO Hans Rosén and CFO Lars-Johan Cederbrant in conference call on October 28 2010 at 11am (CET).
The presentation will be in Swedish.
Date: October 28 2010
Time: 11am Central European Time (CET)
Dial in numbers:
Swedish participants: +46 (0)8 505 629 32
UK participants: +44 (0)207 108 6205
US participants: +1 8666 765 870
A presentation in PDF format will be available on Artimplant's website www.artimplant.com a couple of minutes before the conference call starts.
Artimplant
Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal. Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. The Company's products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on October 25 2010 at 11:30am (CET).